Stanley Rockson is a Cardiology physician affiliated with Stanford University. OpenAlex indexes 348 publications with 11,599 citations (h-index 58); ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 24 Apr 2024.
Clinical trials
- A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema
Sponsor: Stanford University
- Characterization of Treatment Responses in Lymphedema
Sponsor: Stanford University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TACTILE SYSTEMS TECHNOLOGY INCProgram year20252 payments$11,669openpaymentsdata.cms.gov ↗
- Intuitive Surgical, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.8%Beta blocker19.8%Metoprolol Succinate57%Carvedilol43%Part D<11 patientsStatin18%Rosuvastatin Calcium63%Atorvastatin Calcium37%Part D≥16 patients+ 9 more classes in this area
Blood & clotting
9.3%Factor Xa inhibitor9.3%Eliquis100%Part D≥11 patientsMetabolism & gastrointestinal
3.7%SGLT2 inhibitor3.7%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2006–2022 per NIH RePORTER. The latest:
- Prospective evaluation of a surgical solution for breast cancer-associated lymphedema
Fibralign Corporation
FY2019$1,695R44CA203608 - Prospective evaluation of a surgical solution for breast cancer-associated lymphedema
Fibralign Corporation
FY2018$998,174R44CA203608
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Renumathy Dhanasekaran, MD, PhD
Stanford University
Euan Ashley, MD
Stanford University
Sarah Donaldson, MD
Stanford University
Peter Fitzgerald, MD
Stanford University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”